Department of Neuroscience, Janssen Research and Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium.
Faculty of Science and Engineering, Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands.
Sci Rep. 2022 May 11;12(1):7784. doi: 10.1038/s41598-022-11582-1.
Alzheimer's Disease (AD) is a neurodegenerative disease characterized by two main pathological hallmarks: amyloid plaques and intracellular tau neurofibrillary tangles. However, a majority of studies focus on the individual pathologies and seldom on the interaction between the two pathologies. Herein, we present the longitudinal neuropathological and neurophysiological effects of a combined amyloid-tau model by hippocampal seeding of human-derived tau pathology in the APP.PS1/L166P amyloid animal model. We statistically assessed both neurophysiological and pathological changes using linear mixed modelling to determine if factors such as the age at which animals were seeded, genotype, seeding or buffer, brain region where pathology was quantified, and time-post injection differentially affect these outcomes. We report that AT8-positive tau pathology progressively develops and is facilitated by the amount of amyloid pathology present at the time of injection. The amount of AT8-positive tau pathology was influenced by the interaction of age at which the animal was injected, genotype, and time after injection. Baseline pathology-related power spectra and Higuchi Fractal Dimension (HFD) score alterations were noted in APP.PS1/L166P before any manipulations were performed, indicating a baseline difference associated with genotype. We also report immediate localized hippocampal dysfunction in the electroencephalography (EEG) power spectra associated with tau seeding which returned to comparable levels at 1 month-post-injection. Longitudinal effects of seeding indicated that tau-seeded wild-type mice showed an increase in gamma power earlier than buffer control comparisons which was influenced by the age at which the animal was injected. A reduction of hippocampal broadband power spectra was noted in tau-seeded wild-type mice, but absent in APP.PS1 animals. HFD scores appeared to detect subtle effects associated with tau seeding in APP.PS1 animals, which was differentially influenced by genotype. Notably, while tau histopathological changes were present, a lack of overt longitudinal electrophysiological alterations was noted, particularly in APP.PS1 animals that feature both pathologies after seeding, reiterating and underscoring the difficulty and complexity associated with elucidating physiologically relevant and translatable biomarkers of Alzheimer's Disease at the early stages of the disease.
阿尔茨海默病(AD)是一种神经退行性疾病,其特征为两种主要的病理标志:淀粉样斑块和细胞内 tau 神经原纤维缠结。然而,大多数研究都集中在个别病理上,很少关注两种病理之间的相互作用。在此,我们介绍了通过在 APP.PS1/L166P 淀粉样动物模型中海马播散人源性 tau 病理来研究淀粉样蛋白-tau 模型的纵向神经病理学和神经生理学效应。我们使用线性混合模型对神经生理学和病理学变化进行了统计学评估,以确定动物播种时的年龄、基因型、播种或缓冲液、量化病理的脑区以及注射后时间等因素是否会对这些结果产生不同的影响。我们报告说,AT8 阳性 tau 病理逐渐发展,并受到注射时存在的淀粉样蛋白病理数量的促进。AT8 阳性 tau 病理的数量受到动物注射时的年龄、基因型和注射后时间的相互作用的影响。在进行任何操作之前,在 APP.PS1/L166P 中就已经注意到与基线病理相关的功率谱和 Higuchi 分形维数(HFD)评分的改变,表明与基因型相关的基线差异。我们还报告了与 tau 播种相关的脑电图(EEG)功率谱中即刻的局部海马功能障碍,在 1 个月后恢复到类似水平。播种的纵向影响表明,tau 播种的野生型小鼠的 gamma 功率增加早于缓冲液对照比较,这受到动物注射时的年龄的影响。tau 播种的野生型小鼠的海马宽带功率谱减少,但 APP.PS1 动物中没有。HFD 评分似乎可以检测到 APP.PS1 动物中与 tau 播种相关的细微影响,这受到基因型的不同影响。值得注意的是,虽然 tau 组织病理学变化存在,但未观察到明显的纵向电生理变化,尤其是在播种后既有两种病理的 APP.PS1 动物中,这再次强调了在疾病早期阐明与阿尔茨海默病相关的生理相关和可转化的生物标志物的困难和复杂性。